Implications of drugs with rebate in Europe
- PMID: 34557803
- PMCID: PMC8454721
- DOI: 10.1016/j.lanepe.2021.100060
Implications of drugs with rebate in Europe
Conflict of interest statement
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
References
-
- Hofmarcher T., Lindgren P., Wilking N., Jönsson B. The cost of cancer care in Europe 2018. Eur J Cancer. 2020;120:41–49. - PubMed
-
- Prasad V., De Jesús K., Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14:381–390. - PubMed
-
- Vokinger K.N., Hwang T.J., Grischott T. Prices and clinical benefit of cancerdrugs in the USA and Europe: a cost-benefit analysis. Lancet Oncol. 2020;21:664–670. - PubMed
-
- Jommi C. Innovation and drugs price and reimbursement: a comparison between Italy and the other major EU countries. Global Region. Health Technol Assessm. 2015;2:117–124.
LinkOut - more resources
Full Text Sources
